Aimmune Therapeutics Stock Price Target and Analyst Ratings (NASDAQ:AIMT)

Analyst Price Target for AIMT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$33.06

▼ -4.14% Downside Potential

This price target is based on 9 analysts offering 12 month price targets for Aimmune Therapeutics in the last 3 months. The average price target is $33.06, with a high forecast of $58.00 and a low forecast of $15.00. The average price target represents a -4.14% upside from the last price of $34.49.

Hold

The current consensus among 9 contributing investment analysts is to hold stock in Aimmune Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
2 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

9/6/2019

0 strong buy ratings
3 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

12/5/2019

0 strong buy ratings
4 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

3/4/2020

0 strong buy ratings
4 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

6/2/2020

0 strong buy ratings
3 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

8/31/2020

0 strong buy ratings
2 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

11/29/2020

0 strong buy ratings
2 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

1/28/2021

0 strong buy ratings
2 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

2/27/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
9/1/2020	Credit Suisse Group	Boost Price Target	Neutral	$14.00 ➝ $34.50	Low	i
9/1/2020	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$24.00 ➝ $35.00	Low	i Rating by C. Duncan at Cantor Fitzgerald
8/31/2020	Wedbush	Downgrade	Outperform ➝ Neutral	$66.00 ➝ $34.50	Low	i Rating by Liana Moussatos at Wedbush
8/31/2020	Piper Sandler	Downgrade	Overweight ➝ Neutral	$60.00 ➝ $34.50	N/A	i
8/3/2020	Wedbush	Reiterated Rating	Buy	$66.00	Medium	i Rating by Liana Moussatos at Wedbush
7/31/2020	Cantor Fitzgerald	Lower Price Target		$32.00 ➝ $24.00	High	i
7/30/2020	Stifel Nicolaus	Reiterated Rating	Hold	$18.00	High	i Rating by Derek Archila at Stifel Nicolaus
7/29/2020	Credit Suisse Group	Lower Price Target	Neutral	$19.00 ➝ $15.00	Low	i
7/13/2020	Cowen	Initiated Coverage	Outperform	$35.00	Medium	i
5/13/2020	Wedbush	Reiterated Rating	Buy	$66.00	High	i Rating by Liana Moussatos at Wedbush
5/13/2020	Credit Suisse Group	Lower Price Target	Neutral	$29.00 ➝ $19.00	High	i Rating by Evan Seigerman at Credit Suisse Group AG
5/12/2020	HC Wainwright	Lower Price Target	Neutral	$30.00 ➝ $15.00	Medium	i Rating by A. Fein at HC Wainwright
5/11/2020	Stifel Nicolaus	Reiterated Rating	Hold	$32.00 ➝ $20.00	Low	i Rating by Derek Archila at Stifel Nicolaus
3/23/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$64.00 ➝ $32.00	High	i
3/18/2020	Wedbush	Reiterated Rating	Buy	$66.00	Low	i Rating by Liana Moussatos at Wedbush
3/18/2020	JMP Securities	Downgrade	Outperform ➝ Market Perform		High	i
3/17/2020	Robert W. Baird	Lower Price Target	Outperform	$64.00 ➝ $58.00	High	i Rating by Brian Skorney at Robert W. Baird
3/3/2020	Wedbush	Reiterated Rating	Buy	$66.00	N/A	i Rating by Liana Moussatos at Wedbush
3/2/2020	Credit Suisse Group	Lower Price Target		$34.00 ➝ $29.00	High	i Rating by Evan Seigerman at Credit Suisse Group AG
3/2/2020	Stifel Nicolaus	Lower Price Target	Hold	$34.00 ➝ $32.00	High	i Rating by Derek Archila at Stifel Nicolaus
2/28/2020	HC Wainwright	Reiterated Rating	Neutral	$33.00 ➝ $30.00	Medium	i Rating by A. Fein at HC Wainwright
2/26/2020	Wedbush	Reiterated Rating	Buy	$74.00	Medium	i Rating by Liana Moussatos at Wedbush
2/3/2020	Robert W. Baird	Reiterated Rating	Buy	$64.00	High	i Rating by Brian Skorney at Robert W. Baird
2/3/2020	Wedbush	Boost Price Target	Outperform	$79.00 ➝ $81.00	High	i Rating by Liana Moussatos at Wedbush
2/3/2020	JMP Securities	Boost Price Target	Market Outperform	$40.00 ➝ $44.00	High	i
2/3/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$55.00 ➝ $64.00	High	i
2/2/2020	Stifel Nicolaus	Reiterated Rating	Hold	$34.00	High	i Rating by Derek Archila at Stifel Nicolaus
1/23/2020	Roth Capital	Boost Price Target		$45.00 ➝ $50.00	Medium	i
1/21/2020	Wedbush	Reiterated Rating	Buy	$79.00	Medium	i Rating by Liana Moussatos at Wedbush
1/9/2020	Wedbush	Reiterated Rating	Buy	$79.00	Medium	i Rating by Liana Moussatos at Wedbush
12/19/2019	HC Wainwright	Initiated Coverage	Neutral	$33.00	Low	i Rating by A. Fein at HC Wainwright
12/13/2019	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$31.59 ➝ $30.00	Medium	i
10/31/2019	Wedbush	Reiterated Rating	Buy		Medium	i Rating by Liana Moussatos at Wedbush
10/25/2019	The Goldman Sachs Group	Set Price Target	Hold	$27.00	N/A	i Rating by Paul Choi at The Goldman Sachs Group, Inc.
10/9/2019	Piper Jaffray Companies	Set Price Target	Buy	$60.00	N/A	i Rating by Christopher Raymond at Piper Jaffray Companies
9/16/2019	Wedbush	Reiterated Rating	Hold ➝ Outperform	$79.00	Medium	i Rating by Liana Moussatos at Wedbush
9/16/2019	Stifel Nicolaus	Upgrade	Positive		High	i
9/11/2019	Stifel Nicolaus	Boost Price Target	Hold	$24.00 ➝ $30.00	High	i
8/21/2019	Wedbush	Set Price Target	Buy	$79.00	High	i Rating by Liana Moussatos at Wedbush
8/18/2019	Stifel Nicolaus	Reiterated Rating	Hold	$24.00	High	i
8/9/2019	Royal Bank of Canada	Lower Price Target	Outperform	$50.00	Medium	i
7/12/2019	Roth Capital	Initiated Coverage	Buy ➝ Buy	$45.00	Low	i Rating by Z. Jallah at Roth Capital
7/11/2019	Wedbush	Set Price Target	Buy	$79.00	Medium	i Rating by Liana Moussatos at Wedbush
7/2/2019	Wedbush	Reiterated Rating	Buy	$79.00	Low	i Rating by Liana Moussatos at Wedbush
6/6/2019	Wedbush	Reiterated Rating	Outperform	$79.00	Medium	i Rating by Liana Moussatos at Wedbush
5/24/2019	Wedbush	Set Price Target	Buy	$79.00	Low	i Rating by Liana Moussatos at Wedbush
5/21/2019	Credit Suisse Group	Initiated Coverage	Outperform	$36.00 ➝ $30.00	High	i Rating by Vamil Divan at Credit Suisse Group AG
5/9/2019	Wedbush	Reiterated Rating	Buy	$79.00	Low	i Rating by Liana Moussatos at Wedbush
5/9/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$45.00	Medium	i Rating by Charles Duncan at Cantor Fitzgerald
4/11/2019	Cantor Fitzgerald	Reiterated Rating	Buy		Medium	i Rating by Charles Duncan at Cantor Fitzgerald
3/26/2019	Wedbush	Set Price Target	Buy	$79.00	Medium	i Rating by Liana Moussatos at Wedbush
3/19/2019	Wedbush	Lower Price Target	Outperform	$80.00 ➝ $76.00	High	i Rating by Liana Moussatos at Wedbush
3/7/2019	Wedbush	Reiterated Rating	Buy	$80.00	Low	i Rating by Liana Moussatos at Wedbush
2/28/2019	Cantor Fitzgerald	Set Price Target	Buy	$45.00	Medium	i Rating by Charles Duncan at Cantor Fitzgerald
2/26/2019	Wedbush	Reiterated Rating	Buy	$80.00	Medium	i Rating by Liana Moussatos at Wedbush
2/5/2019	Wedbush	Reiterated Rating	Outperform	$80.00	High	i Rating by Liana Moussatos at Wedbush
1/15/2019	Credit Suisse Group	Reiterated Rating	Buy	$40.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
12/20/2018	The Goldman Sachs Group	Set Price Target	Hold	$36.00	High	i Rating by Paul Choi at The Goldman Sachs Group, Inc.
12/13/2018	Wedbush	Set Price Target	Buy	$80.00	Low	i Rating by Liana Moussatos at Wedbush
12/13/2018	Roth Capital	Set Price Target	Buy	$80.00	High	i Rating by Jotin Marango at Roth Capital
12/13/2018	Cantor Fitzgerald	Set Price Target	Buy	$64.00	High	i Rating by Charles Duncan at Cantor Fitzgerald
12/13/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$32.00	High	i Rating by Paul Choi at The Goldman Sachs Group, Inc.
12/12/2018	Credit Suisse Group	Set Price Target	Buy	$40.00	High	i Rating by Vamil Divan at Credit Suisse Group AG
12/9/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$64.00 ➝ $23.75	Low	i Rating by Charles Duncan at Cantor Fitzgerald
12/2/2018	Cantor Fitzgerald	Initiated Coverage	Buy	$64.00	Low	i Rating by C. Duncan at Cantor Fitzgerald
11/23/2018	Cantor Fitzgerald	Reiterated Rating	Overweight		Low	i Rating by C. Duncan at Cantor Fitzgerald
11/19/2018	Credit Suisse Group	Set Price Target	Buy	$40.00	High	i Rating by Vamil Divan at Credit Suisse Group AG
11/19/2018	Roth Capital	Set Price Target	Buy	$80.00	High	i Rating by Jotin Marango at Roth Capital
11/12/2018	Wedbush	Set Price Target	Buy	$80.00	Low	i Rating by Liana Moussatos at Wedbush
11/12/2018	Cantor Fitzgerald	Set Price Target	Buy	$62.00	Low	i Rating by William Tanner at Cantor Fitzgerald
11/11/2018	Stifel Nicolaus	Set Price Target	Hold	$33.00	High	i Rating by Derek Archila at Stifel Nicolaus
11/11/2018	Roth Capital	Set Price Target	Buy	$80.00	High	i Rating by Jotin Marango at Roth Capital
11/9/2018	Credit Suisse Group	Set Price Target	Buy	$40.00	High	i Rating by Vamil Divan at Credit Suisse Group AG
10/17/2018	Wedbush	Initiated Coverage	Buy	$72.00	High	i Rating by Liana Moussatos at Wedbush
10/15/2018	Cantor Fitzgerald	Set Price Target	Buy	$62.00	Low	i Rating by William Tanner at Cantor Fitzgerald
10/9/2018	Roth Capital	Set Price Target	Buy	$80.00	Low	i Rating by Jotin Marango at Roth Capital
9/13/2018	Stifel Nicolaus	Initiated Coverage	Hold	$33.00	High	i
8/13/2018	Credit Suisse Group	Set Price Target	Outperform ➝ Buy	$47.00 ➝ $40.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
6/12/2018	Credit Suisse Group	Set Price Target	Buy	$47.00	Medium	i Rating by Vamil Divan at Credit Suisse Group AG
5/30/2018	Wedbush	Reiterated Rating	Outperform	$72.00	Low	i Rating by L. Moussatos at Wedbush
5/18/2018	Piper Jaffray Companies	Initiated Coverage	Overweight	$60.00 ➝ $30.01	High	i Rating by Charles Duncan at Piper Jaffray Companies
5/10/2018	Credit Suisse Group	Set Price Target	Buy	$47.00	Medium	i Rating by Vamil Divan at Credit Suisse Group AG
5/10/2018	Wedbush	Reiterated Rating	Outperform	$72.00	Medium	i Rating by L. Moussatos at Wedbush
5/9/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$64.00	High	i Rating by W. Tanner at Cantor Fitzgerald
4/5/2018	Piper Jaffray Companies	Set Price Target	Buy	$62.00	Low	i Rating by Charles Duncan at Piper Jaffray Companies
3/6/2018	Wedbush	Reiterated Rating	Outperform	$72.00	High	i Rating by L. Moussatos at Wedbush
3/5/2018	Credit Suisse Group	Set Price Target	Outperform ➝ Buy	$45.00 ➝ $47.00	Medium	i Rating by Vamil Divan at Credit Suisse Group AG
3/5/2018	Roth Capital	Boost Price Target	Buy	$75.00 ➝ $80.00	Low	i Rating by J. Marango at Roth Capital
3/5/2018	Cantor Fitzgerald	Reiterated Rating	Overweight	$64.00	Low	i Rating by W. Tanner at Cantor Fitzgerald
2/27/2018	Royal Bank of Canada	Boost Price Target	Outperform	$62.00	Medium	i
2/27/2018	Piper Jaffray Companies	Set Price Target	Buy	$62.00	Low	i Rating by Charles Duncan at Piper Jaffray Companies
2/27/2018	Credit Suisse Group	Set Price Target	Buy	$45.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
2/23/2018	Wedbush	Reiterated Rating	Buy		Low	i Rating by L. Moussatos at Wedbush
2/20/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$30.00	High	i Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
2/20/2018	Credit Suisse Group	Set Price Target	Buy	$45.00	High	i Rating by Vamil Divan at Credit Suisse Group AG
2/20/2018	Cantor Fitzgerald	Reiterated Rating	Buy		High	i Rating by W. Tanner at Cantor Fitzgerald
2/12/2018	Wedbush	Reiterated Rating	Outperform		Low	i Rating by L. Moussatos at Wedbush
2/7/2018	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$55.00	High	i
1/31/2018	Roth Capital	Boost Price Target	Buy	$60.00 ➝ $75.00	Medium	i Rating by J. Marango at Roth Capital
1/11/2018	Credit Suisse Group	Set Price Target	Buy	$45.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
12/20/2017	Robert W. Baird	Initiated Coverage	Outperform ➝ Outperform	$64.00	Medium	i
12/12/2017	Cantor Fitzgerald	Initiated Coverage	Overweight	$55.00	High	i Rating by W. Tanner at Cantor Fitzgerald
12/5/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$38.00 ➝ $60.00	Low	i Rating by Charles Duncan at Piper Jaffray Companies
12/1/2017	Wedbush	Reiterated Rating	Outperform	$70.00	Low	i
11/20/2017	Roth Capital	Initiated Coverage	Buy ➝ Buy	$60.00	N/A	i Rating by Jotin Marango at Roth Capital
10/23/2017	Credit Suisse Group	Boost Price Target	Outperform	$36.00 ➝ $45.00	N/A	i
10/23/2017	Wedbush	Reiterated Rating	Outperform	$42.00 ➝ $70.00	N/A	i
10/21/2017	Piper Jaffray Companies	Set Price Target	Buy	$38.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
8/14/2017	Wedbush	Reiterated Rating	Ourperform	$42.00	Low	i
7/27/2017	Piper Jaffray Companies	Set Price Target	Buy	$38.00	Low	i Rating by Charles Duncan at Piper Jaffray Companies
7/24/2017	Wedbush	Reiterated Rating	Outperform	$42.00	Medium	i
3/22/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$38.00	Low	i
3/15/2017	Piper Jaffray Companies	Lower Price Target		$38.00	High	i
3/11/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$40.00	N/A	i
2/19/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$40.00	N/A	i
2/17/2017	Wedbush	Reiterated Rating	Outperform	$42.00	N/A	i
2/13/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$40.00	N/A	i
2/8/2017	Wedbush	Reiterated Rating	Outperform	$42.00	N/A	i
12/2/2016	Wedbush	Reiterated Rating	Outperform	$42.00	N/A	i
11/18/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$38.00 ➝ $40.00	N/A	i
11/10/2016	Wedbush	Reiterated Rating	Outperform	$42.00	N/A	i
9/26/2016	JMP Securities	Initiated Coverage	Outperform	$30.00	N/A	i
9/23/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$38.00	N/A	i
9/21/2016	Wedbush	Reiterated Rating	Outperform	$42.00	N/A	i
8/24/2016	Wedbush	Reiterated Rating	Buy	$42.00	N/A	i Rating by Liana Moussatos at Wedbush
8/19/2016	Credit Suisse Group	Reiterated Rating	Buy	$35.00	N/A	i
8/10/2016	Wedbush	Reiterated Rating	Outperform	$42.00	N/A	i Rating by Liana Moussatos at Wedbush
6/29/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$38.00	N/A	i
6/14/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$38.00	N/A	i
6/13/2016	Wedbush	Reiterated Rating	Outperform	$42.00	N/A	i Rating by Liana Moussatos at Wedbush
5/17/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$38.00	N/A	i
5/16/2016	Bank of America	Reiterated Rating	Buy		N/A	i Rating by Ying Huang at Bank of America Co.
5/16/2016	Wedbush	Reiterated Rating	Outperform	$42.00	N/A	i Rating by Liana Moussatos at Wedbush
4/12/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$38.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
3/7/2016	Credit Suisse Group	Lower Price Target	Outperform	$44.00 ➝ $35.00	N/A	i
3/6/2016	Wedbush	Reiterated Rating	Buy	$42.00	N/A	i Rating by Liana Moussatos at Wedbush
2/29/2016	Wedbush	Initiated Coverage	Outperform	$42.00	N/A	i Rating by L. Moussatos at Wedbush
2/29/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$38.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies

(Data available from 2/28/2016 forward)

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Today's Range

Now: $34.49

$34.49

50 Day Range

MA: $34.46

$34.30

$34.59

52 Week Range

Now: $34.49

$10.09

$37.00

Volume

N/A

Average Volume

1,714,599 shs

Market Capitalization

$2.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Aimmune Therapeutics?

The following Wall Street research analysts have issued research reports on Aimmune Therapeutics in the last twelve months: Cantor Fitzgerald, Cowen Inc, Credit Suisse Group AG, HC Wainwright, JMP Securities, Piper Sandler, Robert W. Baird, Stifel Nicolaus, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for AIMT.

What is the current price target for Aimmune Therapeutics?

8 Wall Street analysts have set twelve-month price targets for Aimmune Therapeutics in the last year. Their average twelve-month price target is $33.06, suggesting a possible downside of 4.1%. Robert W. Baird has the highest price target set, predicting AIMT will reach $58.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $15.00 for Aimmune Therapeutics in the next year.
View the latest price targets for AIMT.

What is the current consensus analyst rating for Aimmune Therapeutics?

Aimmune Therapeutics currently has 7 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AIMT, but not buy more shares or sell existing shares.
View the latest ratings for AIMT.

What other companies compete with Aimmune Therapeutics?

Other companies that are similar to Aimmune Therapeutics include Zai Lab, Ascendis Pharma A/S, Arrowhead Pharmaceuticals, ACADIA Pharmaceuticals, United Therapeutics, Ionis Pharmaceuticals, Schrödinger, Sarepta Therapeutics, GW Pharmaceuticals, Evotec, Allakos, Atea Pharmaceuticals, TG Therapeutics, Blueprint Medicines and Turning Point Therapeutics.

How do I contact Aimmune Therapeutics' investor relations team?

Aimmune Therapeutics' physical mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company's listed phone number is 650-614-5220 and its investor relations email address is [email protected] The official website for Aimmune Therapeutics is www.aimmune.com.

NASDAQ:AIMT - Aimmune Therapeutics Stock Price Target and Predictions

Analyst Price Target for AIMT

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Aimmune Therapeutics?

What is the current price target for Aimmune Therapeutics?

What is the current consensus analyst rating for Aimmune Therapeutics?

What other companies compete with Aimmune Therapeutics?

How do I contact Aimmune Therapeutics' investor relations team?